Biotech Strategy Blog

Commentary on Science, Innovation & New Products with a focus on Oncology, Hematology & Cancer Immunotherapy

Posts from the ‘VC & Financing’ category

View of Cambridge and Charles River

Neon Therapeutics is based in Cambridge, MA

One of the much anticipated cancer immunotherapy presentations at the 2017 JP Morgan Healthcare conference was by Neon Therapeutics CEO Hugh O’Dowd.

As readers know we’re riding the Immuno-Oncology wave on Biotech Strategy Blog, and one of the exciting new topics to emerge is whether we can target neoantigens to create personalized immunotherapy.

Our mini-series last year on neonatigens received a lot of attention. It included a primer and three interviews. We were very much of the opinion that Neon Therapeutics is a company to watch out for.

In case you missed them, here are the links:

I highly recommending reading these articles as background on the science and new product development as a prelude to the latest commercialisation update we will cover in today’s post.

What did we learn from the 2017 JP Morgan presentation of the Neon Therapeutics corporate strategy?

If you didn’t make it to the presentation at JPM17 in San Francisco (it wasn’t webcast), you may be interested in this post. This is the latest update in our on-going series on neoantigens and why they matter in cancer immunotherapy.

Subscribers can login to read more

We’re kicking off the first in a mini-series of expert interviews from the 2016 San Antonio Breast Cancer Symposium #SABCS16 with a leading researcher who has discovered a first-in-class compound that shows preclinical promise in several cancers including multi-drug resistant metastatic breast cancer.

It has a novel mechanism of action: 

“Interestingly, it was the only molecule, out of the 150,000 we screened that seemed to work through this pathway.”

To go from “bench to bedside,” and take this drug into the clinic now requires funding beyond what academia can provide.

If you’re at #JPM17 and into early stage VC funding or are in pharma/biotech business development BD&L and are on the look out for an innovative new licensing/investment deal, this post is for you.

What makes this a great story is I heard that one “missing piece of the jigsaw” in working out the pathway through which the drug worked came from unrelated research presented at a seminar on wound healing in zebrafish!

As a 2013 article by Robin McKie in The Observer notes, zebrafish (Danio rerio) share 70% of our genes, which makes them pretty cool research models. They are also transparent.

Hearing this anecdote reminded me of my conversation with Dr William Pao that you can hear on Episode 3 of the Novel Targets Podcast where he astutely said:

 “You never know where things are going to lead, you just have to be able to take advantage of them.”

That could also be a metaphor for life.

Science is about making sense of connections and patterns, which is why funding of basic science is so important. A piece of work by one researcher can unlock a breakthrough by another in a totally unrelated area.

While I was doing this SABCS16 interview, I was also reminded of the story behind the development of enzalutamide, and how AACR past-president Dr Charles Sawyers pitched his UCLA drug discovery work to several major pharma companies, without success, until Dr David Hung at Medivation took the risk… and the rest is history.

What makes that story so surprising is at the time Dr Sawyers already had a track record of success with his work on the development of imatinib!

It was a privilege to talk with a senior scientist at #SABCS16 who has thought outside of the box, made scientific connections, and in the process developed a new drug that shows exciting preclinical promise.

Improving the outcome for cancer patients requires the translation of basic science into new products that enter clinical trials.

I do hope funding will be forthcoming to move this first-in-class drug into the clinic so that’s its potential can be fully evaluated.

Subscribers can login to read more or you can purchase access.

If you’re at #JPM17, it’s a great time to buy a sub to BSB and put it on your expenses!

It’s Wednesday at the 2017 JP Morgan Healthcare Conference and the last full day of the meeting. 

SF Streetcar at Pine StIt’s also our last day for a rolling blog; we hope you’ve enjoyed our coverage and commentary this year.

If you want to catch up on what we’ve written about, do check out our posts form Day 1 (Link) and Day 2 of JPM17 (Link).

Yesterday also included some thoughts on the latest Merck pembrolizumab filing announcement in 1L NSCLC, which has certainly had a dramatic impact on the market, even for big pharma (MRK +$4.9B, BMY -$3.3B).

Companies we’ve covered so far include: Celgene, Incyte, Seattle Genetics, Clovis, Puma, BMS, Five Prime, Nektar, Juno and others.

Subscribers can login to read more

It’s Tuesday at the 2017 JP Morgan Healthcare conference in San Francisco.

San Francisco Streetcar in RainEach day of #JPM17 we’re doing a rolling blog post which we’re updating throughout the day with commentary and insights on the company presentations we’re covering.

While we’re not giving a blow-by-blow account, many companies have the slides readily available, we will be commenting on noteworthy news, and what we learn about pharma/biotech corporate strategy going into 2017.

For those of you who like to catch up with the final summary of each day’s highlights, you can read our post around Day 1 here (Link).

Yesterday we also published a thought leader interview we did with Dr Stephan Grupp, Director of the Cancer Immunotherapy Program at CHOP about some of the latest CAR T cell data and emerging issues we heard at #ASH16 last month (Link).  Do check it out!

Subscribers can login to read more

It’s Day 1 of the 2017 JP Morgan Healthcare Conference in San Francisco…

San Francisco StreetcarDespite the travel challenges associated with the cold weather hitting much of the United States, many have made [or are in the process of making] the “pilgrimage” to hear leading pharma and emerging biotech companies lay out their strategy and goals for the coming year.

Every company that presents at #JPM17 has made their New Year’s resolutions… and like the ones we make personally, some will work out, while others will fall short.

In light of the success of our rolling blog from last years’ JPM conference (link to #JPM16 coverage), we’ve decided to repeat the concept again this year. Throughout the day (schedule permitting) we’ll be updating the post with commentary around news that catches our attention.

If you want to follow along yourself and listen to the company presentations, here’s the link to the JPM17 webcasts and conference agenda (link).

As an aside, in our coverage we will be using JPM followed by the last two digits of the year of the meeting i.e. #JPM17, last year it was #JPM16. This is how the “BioTwitter” community commonly refers to the meeting, and we will be continuing that tradition, notwithstanding the fact that JP Morgan have announced the “official” Twitter hashtag is awkward and long winded #JPMHC35.

Subscribers can login to read more.

Like the Battle of Britain, the cancer immunotherapy landscape is a dynamic one where tactical decisions can make the difference between “winning” and “losing.”

As Bristol Myers recently found out in first-line NSCLC, if you choose the wrong trial design or adopt an overly-aggressive strategy, you can end up losing badly (see post: Detailed thoughts on BMS CheckMate 026 1L trial in NSCLC)

A recent trip to the operations bunker at former RAF Uxbridge, from where the fighters of 11 Group were directed, shows how close we came to losing the Battle of Britain.  Had the German Luftwaffe continued to target RAF airfields instead of diverting their efforts on London, the outcome of the war is likely to have been quite different.

History provides a valuable lesson that strategy and tactics can and do matter; in R&D the targets you choose and how effectively you execute on a plan can make a big difference to outcome.

Battle of Britain Bunker Plot

Pictured: the RAF 11 Group Operations plot as it looked on September 15, 1940.

In Part 2 of the BSB interview with PsiOxus Therapeutics CEO Dr John Beadle, we discuss corporate strategy, and some of the challenges faced by an emerging Biotech company, many of which are likely to be shared by other small companies in the field.

Subscribers can login to read more or you can purchase access.

San Francisco JPM16 Day 3It’s Day 3 of the JP Morgan Healthcare Conference in San Francisco, and we hope that you’re enjoying our commentary and analysis around some of the presentations & news each day. If you’re reading this and aren’t a subscriber already, then why not become one?

We’re not offering a substitute for watching a company presentation yourself, they’re freely available by webcast and several companies have also put up their presentations up on their websites, but in a world awash with information competing for time and attention, we hope we’ve teased out a few of the noteworthy points.

Yesterday, on the Day 2 post we commented on $AMGN, $RHBBY, $BMY, $SGMO, $IMGN and more.

Subscribers can login to read today’s rolling post or you can purchase access.

San Francisco JPM16 Day 2It’s Tuesday at the 2016 JP Morgan Healthcare conference in San Francisco (Twitter #JPM16).

Each day of #JPM16 we’re doing a rolling blog post which we’re updating throughout the day with commentary and insights on the company presentations we’re covering.

While we’re not giving a blow-by-blow account, many companies have the slides readily available, we will be commenting on noteworthy news, and what we learn about corporate strategy going into 2016.

For those of you who like to catch up with the final summary of each day’s highlights, you can read yesterday’s Day 1 synopsis here and our interview with Seattle Genetics CEO, Clay Siegall here.

Subscribers can login or you can purchase access.

San Francisco JPM16 Day 1It’s Day 1 of the annual pilgrimage to San Francisco for the JP Morgan Healthcare conference. In light of the success of the daily rolling blogs we’ve done around the conferences we cover, for the first time we’re doing a rolling blog for each day of #JPM16.

Throughout the day (schedule permitting) we’ll be updating the post with commentary around noteworthy news.

Company presentations mentioned in this post include: $PBYI, $CELG, $GILD, $INCY, $SGEN, $MDVN. There’s also commentary on several of the deals announced by Roche, Juno, Novartis, Sanofi, AstraZeneca & Merck.

If you want to follow along yourself, here’s the link to the JPM16 webcasts & conference agenda.

Subscribers can login to read more.

BIO-CEO-2012-New-York-CityThe 2012 BIO CEO & Investor conference starts today in New York.

The meeting from February 13-14 is being held at the landmark Waldorf-Astoria hotel.

I’m looking forward to seeing some of the iconic hotel features such as the 1893 lobby clock originally produced for the Chicago World Fair.

With Wall Street analysts and investors in mind, the main focus of the 14th annual conference is on publicly traded biotechnology companies.

I expect that a number of the corporate presentations will be webcast, but if you are unable to be in NYC, you can follow the #BIOCEO2012 twitter conversation below:

 

As always, part of the attraction of these events is the opportunity for networking.

Rodman & Renshaw are hosting a party at the Rockefeller Center’s sunken plaza restaurant.

I hope to see you there or at one of the BIO CEO 2012 receptions.

 

Update Waldorf-Astoria Hotel 8.13 am February 13, 2012
I was all set-up with my trusty Zi8 flip camera to record a few clips of Moncef Slaoui’s fireside chat to share with blog readers, but was publicly told off by BIO staff that I could not shoot any video, despite a media registration. The head of media relations for BIO was not readily available when I asked to speak with her about this.

I’m sorry BIO but you’ve lost the plot. There’s no unpublished scientific data at this meeting, no information that is not publicly available, being webcast or being tweeted. If I’m not welcome, I do have other things to do with my time than attend your meeting, write blog posts about, do a video report & tweet about it. #fail

Update Waldorf-Astoria Hotel 8.58 am  February 13, 2012

Waldorf-Astoria-Hotel-Lobby-ClockAfter 20 minutes I have given up waiting for a BIO media rep to talk to about the “no video” policy for this meeting.

If organizations have a specific photo/video policy for a conference they should take the trouble to communicate this beforehand, at registration or prior to a session starts. Nobody bothered to do that at BIO CEO 2012 today. That’s inept organization.

What BIO did communicate by email to those who registered for BIO CEO 2012 in advance was that:

“By registering for this meeting, attendees authorize BIO to use any photographs taken during the Conference, which may be included in promotion materials.” 

BIO could at the same time clearly have indicated any photography/video policy for media or attendees.  They didn’t.

In the absence of any specific instruction otherwise and the fact that all attendees had consented to be photographed, I had no reason to believe that video or photography was prohibited.

What’s more, I shot a video report at BIO 2011 that I am sure the folk at BIO were aware of. I received no complaints about it, and if I shot a video report before it would not be a leap of imagination to expect I might shoot another video report.

Nobody likes to be publicly humiliated or told they can’t do something in a public forum after a session has started.  I certainly didn’t enjoy that happening to me today.

As a result of my experiences at BIO CEO 2012, Biotech Strategy Blog will not be providing any publicity, promotion or coverage of any future BIO event.

I am sorry if this inconveniences any blog readers. However, on reflection, I don’t think it’s a great loss given that there’s no breaking science or clinical trial data presented at any BIO meeting and company presentations are usually webcast or otherwise publicly available.

error: Content is protected !!